

*Place:* Omni Shoreham Hotel, 2500 Calvert Street, N.W., Washington, D.C. 20008.

*Status:* Open to the public, limited only by the space available. Preregistration is recommended, and there is no registration fee. Please obtain registration information from the contact person listed below.

*Purpose:* The agenda will focus on collaborations for health information sharing among the various stakeholders and partners in public health. Papers presented will address the theme, "Partnerships, Technologies, and Communities: Evolving Roles for Health Data." Each day will focus on a public health issue as follows: Day 1, "Health Information Partnerships—National, State, and Local;" Day 2, "Information Technology and Informatics;" and Days 3 and 4, "Communities at Risk." This agenda will cover a broad spectrum of current and future public health concerns. Agenda items are subject to change as priorities dictate.

*Contact Person For More Information:* Substantive program and registration information for the meeting may be obtained from Barbara Butler, Public Health Conference on Records and Statistics, Office of Data Standards, Program Development, and Extramural Programs, NCHS, CDC, Room 1100, Presidential Building, 6525 Belcrest Road, Hyattsville, Maryland 20782, telephone 301/436-7122, extension 144.

Dated: January 28, 1997.

Carolyn J. Russell,

*Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).*

[FR Doc. 97-2580 Filed 1-31-97; 8:45 am]

BILLING CODE 4163-18-P

## Food and Drug Administration

[Docket No. 97F-0035]

### Ashland Chemical Co.; Filing of Food Additive Petition

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing that Ashland Chemical Co. has filed a petition proposing that the food additive regulations be amended to provide for the safe use of polypropylene glycol with a molecular weight of 1,200 to 3,000 as a defoaming agent in water for sliced potatoes.

**DATES:** Written comments on the petitioner's environmental assessment by March 5, 1997.

**ADDRESSES:** Submit written comments to the Dockets Management Branch (HFA-305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1-23, Rockville, MD 20857.

**FOR FURTHER INFORMATION CONTACT:** Vivian M. Gilliam, Center for Food Safety and Applied Nutrition (HFS-

217), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202-418-3167.

**SUPPLEMENTARY INFORMATION:** Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5) (21 U.S.C. 348(b)(5))), notice is given that a food additive petition (FAP 6A4490) has been filed by Ashland Chemical Co., One Drew Plaza, Boonton, NJ 07005. The petition proposes to amend the food additive regulations in § 173.340 *Defoaming agents* (21 CFR 173.340) to provide for the use of polypropylene glycol with a molecular weight of 1,200 to 3,000 as a component of defoaming agents in water for sliced potatoes.

The potential environmental impact of this action is being reviewed. To encourage public participation consistent with regulations promulgated under the National Environmental Policy Act (40 CFR 1501.4(b)), the agency is placing the environmental assessment submitted with the original petition that is the subject of this notice on public display at the Dockets Management Branch (address above) for public review and comment. Interested persons may, on or before March 5, 1997, submit to the Dockets Management Branch (address above) written comments. Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Received comments may be seen in the office above between 9 a.m. and 4 p.m., Monday through Friday. FDA will also place on public display any amendments to, or comments on, the petitioner's environmental assessment without further announcement in the Federal Register. If, based on its review, the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the Federal Register in accordance with 21 CFR 25.40(c).

Dated: January 17, 1997.

Alan M. Rulis,

*Director, Office of Premarket Approval, Center for Food Safety and Applied Nutrition.*

[FR Doc. 97-2532 Filed 1-31-97; 8:45 am]

BILLING CODE 4160-01-F

[Docket No. 96N-0391]

### Review of Infant Formula Nutrient Requirements for Preterm Infants; Announcement of Open Meeting

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) and the Life Sciences Research Office (LSRO) of the Federation of American Societies for Experimental Biology (FASEB) are announcing an open meeting on the review of infant formula nutrient requirements for preterm infants. The LSRO/FASEB has undertaken this review and will prepare a documented scientific report that summarizes the available information. To assist in the preparation of its scientific report, LSRO/FASEB is inviting the submission of scientific data, information, and views bearing on this topic both in writing and orally at the open meeting. **DATES:** The LSRO will hold a 1-day open meeting on this topic on March 26, 1997. The meeting will begin at 9 a.m. Requests to make oral presentations at the open meeting must be submitted in writing and received by March 7, 1997. To be included in the review process, written presentations of scientific data, information, and views should be submitted on or before June 30, 1997. Written materials arriving at LSRO/FASEB on or before March 20, 1997, will be part of the official record of the open meeting.

**ADDRESSES:** The open meeting will be held in the Chen Auditorium, Lee Bldg., Federation of American Societies for Experimental Biology, 9650 Rockville Pike, Bethesda, MD. Written requests to make oral presentations of scientific data, information, and views at the open meeting should be submitted to Daniel J. Raiten (address below) and to the Dockets Management Branch (HFA-305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1-23, Rockville, MD 20857. Two copies of the scientific data, information, and views are to be submitted to each office. These two copies are to be identified with the docket number found in brackets in the heading of this document.

**FOR FURTHER INFORMATION CONTACT:** Daniel J. Raiten, Life Sciences Research Office, Federation of American Societies for Experimental Biology, 9650 Rockville Pike, Bethesda, MD 20814-3998, 301-530-7030 or Linda H. Tonucci, Center for Food Safety and Applied Nutrition (HFS-456), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202-205-5372.